These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19152036)

  • 1. Immunization protocols for use in animal models of candidiasis.
    Segal E; Sandovsky-Losica H
    Methods Mol Biol; 2009; 499():27-34. PubMed ID: 19152036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunisation with the glycolytic enzyme enolase confers effective protection against Candida albicans infection in mice.
    Li Wq; Hu Xc; Zhang X; Ge Y; Zhao S; Hu Y; Ashman RB
    Vaccine; 2011 Jul; 29(33):5526-33. PubMed ID: 21645574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escheriosome mediated cytosolic delivery of Candida albicans cytosolic proteins induces enhanced cytotoxic T lymphocyte response and protective immunity.
    Chauhan A; Swaleha Z; Ahmad N; Farazuddin M; Vasco A; Abida M; Mohammad O
    Vaccine; 2011 Jul; 29(33):5424-33. PubMed ID: 21645572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the usefulness of anti-glyceraldehyde-3-phosphate dehydrogenase antibodies as a treatment for invasive candidiasis in a murine model.
    Gil ML; Dagan S; Eren R; Gozalbo D
    Antonie Van Leeuwenhoek; 2006; 89(3-4):345-50. PubMed ID: 16779630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of candidiasis.
    Clancy CJ; Cheng S; Nguyen MH
    Methods Mol Biol; 2009; 499():65-76. PubMed ID: 19152040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein.
    Tavares D; Ferreira P; Arala-Chaves M
    Microbiology (Reading); 2003 Feb; 149(Pt 2):333-339. PubMed ID: 12624195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasis.
    Xin H
    Vaccine; 2016 Jan; 34(2):245-251. PubMed ID: 26620842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis.
    Montagnoli C; Sandini S; Bacci A; Romani L; La Valle R
    Med Mycol; 2004 Aug; 42(4):319-24. PubMed ID: 15473356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG-ODN combined with Neospora caninum lysate, but not with excreted-secreted antigen, enhances protection against infection in mice.
    Ribeiro DP; Freitas MM; Cardoso MR; Pajuaba AC; Silva NM; Mineo TW; Silva JS; Mineo JR; Silva DA
    Vaccine; 2009 Apr; 27(19):2570-9. PubMed ID: 19428863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.
    Spellberg BJ; Ibrahim AS; Avanesian V; Fu Y; Myers C; Phan QT; Filler SG; Yeaman MR; Edwards JE
    J Infect Dis; 2006 Jul; 194(2):256-60. PubMed ID: 16779733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida antigens and immune responses: implications for a vaccine.
    Moragues MD; Rementeria A; Sevilla MJ; Eraso E; Quindos G
    Expert Rev Vaccines; 2014 Aug; 13(8):1001-12. PubMed ID: 24957934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saccharomyces as a vaccine against systemic candidiasis.
    Liu M; Clemons KV; Johansen ME; Martinez M; Chen V; Stevens DA
    Immunol Invest; 2012; 41(8):847-55. PubMed ID: 22686468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral immunization against mucosal candidiasis in a mouse model.
    Rahman D; Challacombe SJ
    Adv Exp Med Biol; 1995; 371B():1663-6. PubMed ID: 7502878
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.
    Xin H; Cutler JE
    Clin Vaccine Immunol; 2011 Oct; 18(10):1656-67. PubMed ID: 21832099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoproteomic analysis of the protective response obtained from vaccination with Candida albicans ecm33 cell wall mutant in mice.
    Martínez-López R; Nombela C; Diez-Orejas R; Monteoliva L; Gil C
    Proteomics; 2008 Jul; 8(13):2651-64. PubMed ID: 18546157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine potential of plasma bead-based dual antigen delivery system against experimental murine candidiasis.
    Ahmad E; Zia Q; Fatima MT; Owais M; Saleemuddin M
    Int J Biol Macromol; 2015 Nov; 81():100-11. PubMed ID: 26231333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.
    Segal E
    Methods Mol Biol; 2017; 1625():343-353. PubMed ID: 28585001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strain-dependent migration of lymphocytes to the vaginal mucosa after peripheral immunization.
    Mulero-Marchese RD; Blank KJ; Sieck TG
    Immunogenetics; 1999 Oct; 49(11-12):973-80. PubMed ID: 10501840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of mice against Coccidioides immitis intranasal infection by vaccination with recombinant antigen 2/PRA.
    Shubitz L; Peng T; Perrill R; Simons J; Orsborn K; Galgiani JN
    Infect Immun; 2002 Jun; 70(6):3287-9. PubMed ID: 12011027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of passive sensitization by cross-reacting antibodies and of active immunization by cross-reacting microbial antigens for the development of an immunopathologic process].
    Ogurtsov RP
    Vestn Akad Med Nauk SSSR; 1974; (11):30-4. PubMed ID: 4615469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.